Sarcoidosis therapeutics market size to grow by USD 64.82 million from 2021 to 2026: Rising awareness about sarcoidosis to boost the market - Technavio

NEW YORK, April 5, 2023 /PRNewswire/ -- The global sarcoidosis therapeutics market size is estimated to grow by USD 64.82 million from 2021 to 2026, according to Technavio. The market is estimated to grow at a CAGR of 4.79% during the forecast period. Moreover, the growth momentum will accelerate. The market growth will be driven by factors such as rising awareness about sarcoidosis, special regulatory designations, and increasing funding for research on sarcoidosis. However, the increasing competition from generics may impede market growth during the forecast period. For more insights on the forecast market size (2022 to 2026) - Request a sample report

The increasing awareness about sarcoidosis is driving the market growth. Various government and non-government organizations, such as the Foundation for FSR and the National Heart, Lung and Blood Institute (NHLBI) of the NIH, are working on improving awareness about sarcoidosis and its treatment. The Sarcoidosis Network Foundation (SNF) promotes education about sarcoidosis. It also supports research to find the cure and prevention of this disease and improve the quality of life of affected patients in the US. The British Lung Foundation (BLF) also raises awareness about the disease, including its causes, symptoms, diagnosis, and treatment in the UK. Such factors will fuel the market growth during the forecast period.

Sarcoidosis therapeutics market – Vendor analysis

This report analyzes the market's competitive landscape and offers information about various market vendors. Some of the key vendors and their offerings are listed below:

• Alembic Pharmaceuticals Ltd. - The company offers sarcoidosis therapeutics through its Methotrexate 50 MG/2ML solution. 
• Amneal Pharmaceuticals Inc. - The company offers sarcoidosis therapeutics through its Methotrexate tablets.
• Antares Pharma Inc. - The company offers sarcoidosis therapeutics named OTREXUP (methotrexate) injection.
• Fresenius SE and Co. KGaA - The company offers sarcoidosis therapeutics through its Methotrexate Injection, USP.
• Horizon Therapeutics Plc - The company offers sarcoidosis therapeutics named RAYOS (prednisone).
• Apotex Inc.
• Azurity Pharmaceuticals Inc.
• Cadila Healthcare Ltd.
• Dr. Reddys Laboratories Ltd.
• Hikma Pharmaceuticals Plc
• Intas Pharmaceuticals Ltd.
• Mallinckrodt Plc
• Medexus Pharmaceuticals Inc.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Johnson and Johnson Inc.

Why buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio – Buy the report!

Sarcoidosis therapeutics market - Segmentation assessment
Segment overview
Technavio has segmented the market based on product (corticosteroids and other therapeutics) and geography (North America, Europe, Asia, and Rest of World (ROW)). 

• The corticosteroids segment will account for a significant share of the market growth during the forecast period. Corticosteroids are medications that perform anti-inflammatory and immune suppression activities. They are primarily used for the treatment of sarcoidosis. Therefore, factors such as the increase in the application of corticosteroids are driving the growth of this segment.

Geography overview
The report provides actionable insights and estimates the contribution of all regions to the growth of the global sarcoidosis therapeutics market.

• North America will account for 38% of the market's growth during the forecast period. The US and Canada are the key contributors to the sarcoidosis therapeutics market in the region. Moreover, market growth in North America will be faster than the growth of the market in Rest of World (ROW). The rise in awareness about sarcoidosis in key countries such as the US and Canada will drive the sarcoidosis therapeutics market growth in the region during the forecast period.

Insights on the market contribution of various segments, including country- and region-wise data and forecast market size (2022 to 2026) - Download a sample report

Sarcoidosis therapeutics market – Market dynamics

Leading trends influencing the market 

• The novel drug pipeline for sarcoidosis is a key trend influencing market growth.
• For instance, Relief Therapeutics is developing aviptadil, which targets vasoactive intestinal peptide receptors.
• Araim Pharmaceuticals is in the process of developing a peptide called cibinetide, which has shown agonist activity at the innate repair receptor (IRR).
• Therefore, the development of such drugs is expected to support market growth during the forecast period.

Major challenges hindering the market growth

• The increasing competition from generics is challenging market growth.
• Generic drugs gain marketing approval in less time when compared to innovator drugs.
• The development of generic drugs is simple, less time-consuming, and requires lower R&D expenditure than innovator drugs, as preclinical and clinical studies are not required for generic versions.
• Azimune (azathioprine), RAYOS (prednisone), Remicade (infliximab), and Predyl-O (prednisolone) are some of the generic drugs for the treatment of sarcoidosis.
• Therefore, a rise in demand for generics is expected to hinder the growth of the global sarcoidosis therapeutics market during the forecast period.

Insights on market drivers, trends, and challenges and forecast period (2022 to 2026) - Request a sample report!

What are the key data covered in this sarcoidosis therapeutics market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the sarcoidosis therapeutics market between 2022 and 2026
• Precise estimation of the size of the sarcoidosis therapeutics market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the sarcoidosis therapeutics market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of sarcoidosis therapeutics market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The autoimmune hemolytic anemia therapeutics market size is expected to grow by USD 268.22 million from 2021 to 2026 at an accelerating CAGR of 9.1%. The market is segmented by product (corticosteroids, monoclonal antibodies, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The regulatory incentives are notably driving the autoimmune hemolytic anemia therapeutics market growth, although factors such as lack of effective therapies may impede the market growth.

The anti-inflammatory therapeutics market size is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The anti-inflammatory therapeutics market size is forecasted to increase by USD 39.32 billion. The market is segmented by application (RA, psoriasis, and MS), drug class (anti-inflammatory biologicals, corticosteroids, and NSAIDs), and geography (North America, Europe, Asia, and Rest of World). The unmet need for safer biologics for RA is notably driving the market growth, although factors such as the loss of patents may impede the anti-inflammatory drugs market growth.

Browse for Technavio Health Care market reports

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Corticosteroids - Market size and forecast 2021-2026
• Exhibit 28: Chart on Corticosteroids - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Corticosteroids - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Corticosteroids - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Corticosteroids - Year-over-year growth 2021-2026 (%)

• 5.4 Other therapeutics - Market size and forecast 2021-2026
• Exhibit 32: Chart on Other therapeutics - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Other therapeutics - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Other therapeutics - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Other therapeutics - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Product 
• Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 Alembic Pharmaceuticals Ltd. 
• Exhibit 85: Alembic Pharmaceuticals Ltd. - Overview
• Exhibit 86: Alembic Pharmaceuticals Ltd. - Product / Service
• Exhibit 87: Alembic Pharmaceuticals Ltd. - Key offerings

• 10.4 Amneal Pharmaceuticals Inc. 
• Exhibit 88: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 89: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 90: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 91: Amneal Pharmaceuticals Inc. - Segment focus

• 10.5 Antares Pharma Inc. 
• Exhibit 92: Antares Pharma Inc. - Overview
• Exhibit 93: Antares Pharma Inc. - Business segments
• Exhibit 94: Antares Pharma Inc. - Key news
• Exhibit 95: Antares Pharma Inc. - Key offerings
• Exhibit 96: Antares Pharma Inc. - Segment focus

• 10.6 Fresenius SE and Co. KGaA 
• Exhibit 97: Fresenius SE and Co. KGaA - Overview
• Exhibit 98: Fresenius SE and Co. KGaA - Business segments
• Exhibit 99: Fresenius SE and Co. KGaA - Key offerings
• Exhibit 100: Fresenius SE and Co. KGaA - Segment focus

• 10.7 Horizon Therapeutics Plc 
• Exhibit 101: Horizon Therapeutics Plc - Overview
• Exhibit 102: Horizon Therapeutics Plc - Business segments
• Exhibit 103: Horizon Therapeutics Plc - Key news
• Exhibit 104: Horizon Therapeutics Plc - Key offerings
• Exhibit 105: Horizon Therapeutics Plc - Segment focus

• 10.8 Intas Pharmaceuticals Ltd. 
• Exhibit 106: Intas Pharmaceuticals Ltd. - Overview
• Exhibit 107: Intas Pharmaceuticals Ltd. - Product / Service
• Exhibit 108: Intas Pharmaceuticals Ltd. - Key offerings

• 10.9 Johnson and Johnson Inc. 
• Exhibit 109: Johnson and Johnson Inc. - Overview
• Exhibit 110: Johnson and Johnson Inc. - Business segments
• Exhibit 111: Johnson and Johnson Inc. - Key news
• Exhibit 112: Johnson and Johnson Inc. - Key offerings
• Exhibit 113: Johnson and Johnson Inc. - Segment focus

• 10.10 Mallinckrodt Plc 
• Exhibit 114: Mallinckrodt Plc - Overview
• Exhibit 115: Mallinckrodt Plc - Business segments
• Exhibit 116: Mallinckrodt Plc - Key news
• Exhibit 117: Mallinckrodt Plc - Key offerings
• Exhibit 118: Mallinckrodt Plc - Segment focus

• 10.11 Medexus Pharmaceuticals Inc. 
• Exhibit 119: Medexus Pharmaceuticals Inc. - Overview
• Exhibit 120: Medexus Pharmaceuticals Inc. - Key offerings

• 10.12 Pfizer Inc. 
• Exhibit 121: Pfizer Inc. - Overview
• Exhibit 122: Pfizer Inc. - Business segments
• Exhibit 123: Pfizer Inc. - Key news
• Exhibit 124: Pfizer Inc. - Key offerings
• Exhibit 125: Pfizer Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 126: Inclusions checklist
• Exhibit 127: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 128: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 129: Research methodology
• Exhibit 130: Validation techniques employed for market sizing
• Exhibit 131: Information sources

• 11.5 List of abbreviations 
• Exhibit 132: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio